TABUTEAU HERRIOT sold $12.0M of AXSM
TABUTEAU HERRIOT (Chief Executive Officer) sold 49,670 shares of Axsome Therapeutics, Inc. (AXSM) at $241.01 ($11.97M total) on 2026-06-09 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The main tradable takeaway is sentiment/positioning optics from a sizable insider sale; however, the 10b5-1 designation suggests the timing was predetermined.
Market read
Material insider selling disclosed today, but pre-arranged 10b5-1 reduces the likelihood of a new negative fundamental signal.
What to watch
The filing doesn’t disclose intent beyond the plan; traders should avoid extrapolating fundamentals from a single scheduled sale without corroborating news (trial/regulatory/financing).
Background
The article is an SEC Form 4 insider transaction disclosure (open-market sale) by Axsome’s CEO/10% owner.
Ticker impact
Axsome CEO TABUTEAU HERRIOT sold 49,670 shares for ~$11.97M via an open-market sale under a pre-arranged 10b5-1 plan.
Near-term drift risk (sell-overhang optics), but likely limited fundamental impact given 10b5-1 pre-arrangement.
The filing is primary-source and material in size, yet it explicitly states a pre-arranged 10b5-1 plan, which typically dampens inference about new negative information.
Market effects
No direct sector read-through; this is company-specific insider liquidity/positioning rather than a clinical/regulatory catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is executed under a pre-arranged 10b5-1 plan, it may reflect routine diversification rather than bearish expectations.
Key entities
- issuerAxsome Therapeutics, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderTABUTEAU HERRIOT
CEO, officer/director, and 10% owner who sold shares.
